Rabitat, India’s fastest-growing D2C brand has successfully raised INR 40 crore (USD $5 million) in its Series A funding round. The round was exclusively advised by Accurize StartGrowers, a boutique capital advisory and syndication firm focused on high-growth consumer ventures.

Vivek Kakkar, Founder, Accurize Startgrowers Pvt. Ltd.

Vivek Kakkar, Founder of Accurize StratGrowers, commented,“Rabitat is not just building products-it’s pioneering a movement around safer, smarter parenting choices. By merging certified food safety standards with world-class design, Rabitat is well-positioned to lead the next wave of innovation in food contact products (FCP) and conscious parenting essentials.”

Accurize Investor Syndicate also participated in the round, underscoring deep alignment between the advisory platform and the brand’s growth journey.

The funding round was led by RPSG Capital Ventures and DSG Consumer Partners, with participation from Capital A, Flair Writing Family Office, Eaglewings Ventures, and leading angel investors including founders from The Souled Store, LivSpace etc.

Rabitat addresses the critical need for safe, functional, and stylish kids food contact products. The company offers BPA-free, non-toxic drinkware and foodware made from globally certified materials, combining child-safe features with appealing aesthetics.

About Accurize
Founded in 2022 Accurize StratGrowers is a strategic growth advisory and capital syndication platform enabling growth-stage ventures across consumer, retail, and digital ecosystems. The firm specializes in high-impact fundraising mandates, M&A, go-to-market strategy and building long term capability for mission-driven businesses.

For more information, please visit www.accurize.co/

Small cap funds are known for their potential to deliver higher returns in the long run. These funds invest in companies with a smaller market capitalization-typically those ranked 251 and beyond on recognised stock exchanges. While these businesses are often in their early or expansion stages and have significant growth potential, they can also be more sensitive to market swings compared to large cap counterparts.

That’s why managing volatility is key-and one potential way to do that is through a Systematic Investment Plan (SIP). SIPs help bring discipline to your investing journey while potentially cushioning short-term ups and downs.

The Bajaj Finserv Small Cap Fund NFO ends on June 11, 2025

If you’re seeking to enter the small cap space, you can consider the Bajaj Finserv Small Cap Fund. Launched on June 27, 2025, this new equity fund seeks to manage risk through a structured approach and an emphasis on quality businesses with long-term growth potential and favourable valuations. The fund is currently in its New Fund Offer (NFO) period, which remains open until July 11, 2025.

Why consider a small cap fund

If you are an investor with a higher risk appetite, a small cap fund can be a suitable investment for you in the long term. These funds tend to perform across different market cycles, and their returns may not follow typical patterns in the short term. So, while this creates opportunity, it also means that these funds are more sensitive to market conditions and investor sentiment.

How SIPs help navigate volatility

Volatility is an inherent part of small cap investing. One way to mitigate risks in these funds is by spreading out your investment over time through an SIP. An SIP allows you to invest a fixed amount at regular intervals, typically monthly.

SIPs are powered by features like the power of compounding and rupee cost averaging. Here, when markets are low, you buy more SIP units; when the market is high, you buy fewer. Over time, this helps average out your purchase price, which may result in better risk mitigation.

An SIP also helps you build consistency and discipline-making investing a habit, not a one-time decision. This discipline is especially useful in volatile segments such as small cap funds.

Aligning SIPs with long-term goals

When you start an SIP in a small cap fund, you get an opportunity to better align your contribution plan with your financial goals. Whether youre saving for retirement, a child’s education, or building a long-term corpus, having clarity on your objective can help guide how much you invest and for how long.

The longer you stay invested in a small cap fund, the more time it allows you to potentially recover from short-term fluctuations and build long-term wealth. Since small cap funds take time to realise their growth potential, patience is a key part of the process.

What to look for when selecting a small cap fund

Before starting a SIP in a small cap fund, consider evaluating a few important aspects:

• Investment approach: How does the fund seek to mitigate risk and deliver the potential for long-term growth Review the strategy in detail.

• Fund manager expertise: The ability to identify promising small cap companies requires skill. Look into the manager’s approach and investment philosophy.

• Expense ratio: Over the long term, even small differences in cost can affect your returns.

• Portfolio diversification: Check how diversified the fund is across sectors and companies. A more balanced portfolio may reduce the impact of underperformance in any one stock.

SIP investment: A steady way to participate

An SIP investment in a small cap fund may allow investors to benefit from the potential upside while managing exposure to risk. By contributing steadily over time, investors may feel less pressure to time the market and more confidence in sticking with their long-term plan.

Even modest SIP investments, if continued consistently, can add up over time and potentially contribute meaningfully to financial goals.

Conclusion
Small cap funds can offer long-term growth potential, but their higher volatility means they may not suit every investor. Starting a SIP investment in a small cap fund-such as the Bajaj Finserv Small Cap Fund (NFO open till July 11, 2025)-may help smooth out the experience, providing a disciplined and gradual approach to building wealth over time. As always, it is advisable to speak with a financial advisor to ensure that your investment choices align with your overall goals and comfort with risk.

To invest in the Bajaj Finserv Small Cap Fund NFO or learn more about the fund, visit www.bajajamc.com.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

• Continues to build a full-stack Ayurveda enterprise with focus on comprehensive precision Ayurveda care and integrative medicine for patients across various clinical conditions

• Launches 50 SKUs across classical Ayurveda formulations, OTC products, and medical foods

• Targets nationwide reach and Rs. 500 crores in Products revenue in the next 5 years

Apollo AyurVAID, India’s leading NABH-accredited, precision Ayurveda hospital network, announces its strategic foray into the Ayurveda product segment, marking a significant expansion beyond clinical care. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated Ayurveda products in India’s ~ Rs. 60,000 crore market growing at over 16% annually.

Apollo AyurVAID launches India’s first ‘Tested Safe’ Ayurveda products

In an industry first, Apollo AyurVAID’s product range features clinically proven formulations that are certified safe by NABL-accredited laboratories with respect to presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. Apollo AyurVAID’s products set the highest, proof-backed, safety benchmark in the Ayurveda product market with the consumer able to verify test results (QR code on packaging) for each and every product they consume. This reinforces Apollo AyurVAID’s resolve to offer safer, standardised, and effective Ayurveda products that the market can implicitly trust.

Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID said, “Apollo AyurVAID’s foray into tested-safe Ayurveda products marks a pivotal step in redefining standards of safety, transparency, and efficacy in traditional medicine. This expansion builds on a strong foundation of clinical excellence and reflects a deep commitment to evidence-based, precision Ayurveda. By integrating innovation with time-honoured wisdom, Apollo AyurVAID is well on its way to shaping the future of integrative medicine in India and beyond.”

Commenting on this strategic initiative, Mr. Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID said, “With two decades of clinical excellence behind us, we are extending our understanding of precision Ayurveda and credibility into a high-potential consumer space. This new vertical not only complements our inpatient-outpatient care model but also opens scalable revenue opportunities and reinforces our vision of mainstreaming evidence-based Ayurveda services and products by making it accessible globally. We anticipate this portfolio will be a key growth driver, with a revenue aspiration of Rs. 500 crores in the next 5 years.”

The Ayurveda products division is being developed as a business unit of Apollo AyurVAID, while staying firmly rooted in Apollo AyurVAID’s commitment to precision Ayurveda for personalised, safe, clinical-outcomes-driven health care.. While classical formulations will be available through prescription, the OTC and medical foods lines will be available through a wide network of retail and digital platforms. The OTC range features innovative medicine formats such as creams, transdermal pads, essential extracts, etc., for special customer segments (women, child, elder, etc.) and applications (pain, sleep, stress, skin etc.), with highest medical content assuring best-in-class product performance. Apollo AyurVAID has recently partnered with integrated systems biology platform company, Avesthagen Limited, to co-develop and offer scientifically validated, botanical-actives based dietary supplements that are sugar-free, artificial colour & flavours free; this shall be followed with an Ayurveda based medical foods range for specific clinical indications.

The classical and OTC product range are branded ‘AyurVAID‘ while the dietary supplements are branded ‘AvestaAyurVAID’. This strategic expansion reinforces Apollo AyurVAID’s vision of building a credible, science-led ecosystem for precision Ayurveda and evolving into a full-spectrum Ayurveda company.

“As we enter the Ayurveda products space, our broader vision is to take the Apollo AyurVAID brand across the length and breadth of India.In the current fiscal we plan to expand our hospital network in an asset-light manner by adding 9 new points of presence, scaling our bed capacity to 350, aiming to treat over 50,000 patients. With a CAGR of 75% over the last 2-3 years, we are on track to surpass the annualised Rs. 100 crore revenue mark by mid next year – an unprecedented milestone in Ayurveda’s services sector. This is just the beginning of our journey to take Apollo AyurVAID, India’s most credible, precision Ayurveda care, to every corner of the country and across the globe,” added Mr. Rajiv Vasudevan.

Distribution for the new portfolio will follow a multi-tier strategy, with availability across Apollo AyurVAID’s hospitals and clinics, the company’s website, Apollo Pharmacies, Apollo 24|7 and leading e-commerce platforms. This integrated channel approach is designed to enable access and reach to a wider audience.

About Apollo AyurVAID

Apollo AyurVAID (www.ayurvaid.com) is India’s leading chain of protocol-driven Ayurveda hospitals and integrative care centres, delivering evidence-based, ‘Precision Ayurveda’ for chronic disease reversal, management, and sustained wellbeing. Since its inception in 2005, Apollo AyurVAID has been committed to transforming Ayurveda into a mainstream, protocols, documentation and clinical-outcomes driven system of medicine with hospitals and clinics spread across Bengaluru, Chennai, New Delhi, Kochi, Almora and Hyderabad.

Founded in 2005 and part of the Apollo group since 2022, Apollo AyurVAID has emerged as a pivotal force in formalising Ayurveda-led integrative care, developing a unique care model that combines traditional Ayurvedic wisdom with modern clinical rigour. The chain of hospitals has demonstrated an impactful model of integrative care across specialties including neurology, oncology, nephrology, obstetrics and gynaecology, and metabolic disorders, with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention. Apollo AyurVAID’s unique ‘Whole Person Care’ approach considers the whole person to treat multimorbidity, not just at symptom level but at root-cause level, and supports health across the entire life cycle, from prevention and treatment to rehabilitation, survivorship and wellbeing.

The first and only Ayurveda institution to receive the prestigious QCI DL Shah National Quality Award (2012), Apollo AyurVAID is also India’s first NABH-accredited Ayurveda hospital (2010). It is also the first to gain NABH accreditation for Ayurveda para surgery (2013) and five hospitals in its countrywide network are NABH-accredited. In 2023, it became the first and only QAI-accredited Ayurveda and integrative medicine based Transition Care Centre in India.

Paisabazaar, India’s leading consumer credit marketplace and free credit score platform, today announced the launch of the Paisabazaar Credit Premier League, a nationwide contest to identify India’s most credit-healthy consumers.

Who’s Got the Best Credit Score Paisabazaar Credit Premier League Aims to Find India’s Credit-Healthy Heroes

The contest is open to both existing Paisabazaar consumers and new users who check their credit score on the Paisabazaar platform – via the website or mobile app – during the contest period, July 5 to August 5, 2025.

Participants can track their All-India Rank, as well as city-wise and age-wise rankings, and view the leader board exclusively on the Paisabazaar app. The contest will reward top-ranked consumers from across the country with exciting prizes, including iPhones and Amazon vouchers.

According to Paisabazaar, the Credit Premier League aims to make the journey towards good credit health engaging and rewarding, while also building greater awareness about the importance of maintaining a strong credit profile.

Santosh Agarwal, CEO, Paisabazaar, said, “Despite credit score being one of the most important indicators of our financial health, conversations around it are still rare. With the Credit Premier League, we want to make credit score mainstream. The contest adds a fun, competitive edge to the process, and we hope it encourages more consumers to actively track, improve, and talk about their credit health.”

Consumers can participate by simply checking their free credit score on the Paisabazaar app or website during the contest period. Those with strong credit profiles stand a chance to climb the ranks and win prizes.

About Paisabazaar
Paisabazaar, a part of PB Fintech (listed since 2021), is India’s largest marketplace for consumer credit and free credit score. Over the last 11 years, Paisabazaar has earned the trust of over 50 million consumers and it handles 20 lakh+ monthly enquiries from 1000+ cities. Paisabazaar has built 65+ partnerships withBanks, NBFCs, and fintechs to offer a broad range of credit products. Paisabazaar is ISO.

(27001:2013) and PCI DSS certified organisation, with industry-best controls, to safeguard the best interest of consumers.

Manipal Academy of Higher Education (MAHE) proudly acknowledges the generous contribution of Rs. 1 crore from Siemens Healthineers India which funded state-of-the-art Therapy Block at the Manipal Hospice and Respite Centre (MHRC). This vital support will significantly enhance the quality of palliative and rehabilitative care provided to patients and families, reinforcing MAHE’s commitment to compassionate healthcare.

Siemens Healthineers supports Manipal Hospice Therapy Block

The Manipal Hospice and Respite Care was inaugurated in May 2025 by the Honble Justice Shri S Abdul Nazeer, His Excellency the Governor of Andhra Pradesh, and was operational from June 2025.

The Therapy Block at MHRC is a 6,100-square-foot facility, which has been meticulously designed to provide comprehensive rehabilitative and supportive care, featuring dedicated spaces for physiotherapy, occupational therapy, mind-body therapy, speech and swallow therapy, home-based occupational therapy, and counseling. The Therapy Block aims to enhance the comfort, independence, and dignity of patients, addressing their physical, cognitive, and emotional needs.

Speaking on the collaboration, Hariharan Subramanian, Managing Director of Siemens Healthcare Pvt Limited said, “The Therapy Block at the Manipal Hospice and Respite Centre, a pioneering hospice care initiative in India, addresses critical unmet needs of terminally ill patients. Our collaboration with MAHE to establish this therapy block reflects our shared commitment to fostering positive health outcomes and enhancing societal well-being within the communities we serve.”

Driving Impact Through Collaboration

This contribution is part of Siemens Healthineers’ broader vision to pioneer breakthroughs in healthcare for everyone, everywhere. The company’s partnership with Manipal Academy of Higher Education (MAHE) exemplifies the impact of industry-academia collaboration in transforming care delivery and supporting healthcare providers across the patient care continuum-from prevention and early detection to diagnosis, treatment, and aftercare.

Applauding collaboration with Siemens Healthineers’ on this high-impact social initiative Lt Gen (Dr) MD Venkatesh, VSM (Retd) Vice Chancellor of MAHE, stated, “MHRC is a pathbreaking initiative that advances our mission to deliver specialized, empathetic, and academically rooted healthcare. The support from Siemens Healthineers and other partners has been instrumental in realizing this vision.”

Manipal Hospice and Respite Centre, a 100-bed facility spread over 12 acres, is the first hospice in India to be affiliated with both a hospital and a university. It is the second largest hospice in India and aims to serve both patients with cancer and non-cancer. This hospice offers respite care as well as end-of-life care for both adults and children.

About Siemens Healthineers

Siemens Healthineers pioneers’ breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com

Siemens Healthineers in India has a countrywide sales network and round-the-clock service set-up, two manufacturing facilities at Vadodara for Diagnostics and at Bengaluru for Medical Imaging Products, backed by a state-of-the-art R&D center as well as a global software development center at Bengaluru. With over 7,000 employees across the nation, Siemens Healthineers is playing a significant role in transforming care delivery in India and supporting healthcare providers across the entire range of patient care-from prevention and early detection to diagnosis, treatment, and aftercare. Further information is available at www.siemens-healthineers.co.in.

About Manipal Academy of Higher Education

The Manipal Academy of Higher Education (MAHE) is an Institution of Eminence Deemed-to-be University. MAHE offers over 400 specializations across the Health Sciences (HS), Management, Law, Humanities & Social Sciences (MLHS), and Technology & Science (T&S) streams through its constituent units at campuses in Manipal, Mangalore, Bengaluru, Jamshedpur, and Dubai. With a remarkable track record in academics, state-of-the-art infrastructure, and significant contributions to research, MAHE has earned recognition and acclaim both nationally and internationally. In October 2020, the Ministry of Education, Government of India, awarded MAHE the prestigious Institution of Eminence status. Currently ranked 4th in the National Institutional Ranking Framework (NIRF), MAHE is the preferred choice for students seeking a transformative learning experience and an enriching campus life, as well as for national & multi-national corporates looking for top talent.